Market revenue in 2024 | USD 22.5 million |
Market revenue in 2033 | USD 78.5 million |
Growth rate | 14.9% (CAGR from 2025 to 2033) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2021 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2033 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 69.33% in 2024. Horizon Databook has segmented the South Africa head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2021 to 2033.
The South Africa head and neck cancer therapeutics market is competitive owing to the local presence of multiple global players and domestic manufacturers. The increasing prevalence and incidence of head and neck cancer and rising awareness about the treatment procedures are among the leading factors driving the country’s market.
In addition, the presence of a large number of profit and nonprofit organizations that promote awareness about cancer screening and diagnosis is expected to support market expansion. For instance, The Cancer Association of South Africa encourages women and men to undergo routine health checkups & cancer screening.
The registration of pharmaceuticals in South Africa is directed by the South African Health Products Regulatory Authority (SAHPRA) with the Medicine Control Council (MCC) under the Medicines and Related Substances Control Act 1965 (Act 101 of 1965).
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into South Africa head and neck cancer therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
No related statistics found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account